Food and Drug Administration – Shortage of Vyvanse® (lisdexamfetamine) and generics

- Brand Vyvanse (lisdexamfetamine) and generics are in shortage due to increased demand and limited availability of active ingredient due to quotas set by the Drug Enforcement Agency (DEA) for controlled substances. Both capsules and chewable tablets are in short supply.
- Brand and generic Vyvanse are FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.
- Amphetamine products are CII controlled substances. Production is controlled by the DEA and distribution quantities are closely monitored and regulated making it difficult to rapidly increase supply.
- The FDA shortage site provides updates on the shortage, including a list of current manufacturers and product strengths that are still available.